Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women

AIDS

Volumn 22, Issue 11, 2008, Pages 1355-1363

  Cook, Judith A ^a   Burke Miller, Jane K ^a   Cohen, Mardge H ^b   Cook, Robert L ^c   Vlahov, David ^d   Wilson, Tracey E ^e   Golub, Elizabeth T ^f   Schwartz, Rebecca M ^e   Howard, Andrea A ^g   Ponath, Claudia ^h   Plankey, Michael W ⁱ   Levine, Andrea ^j   Grey, Dennis D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Jr Hospital of Cook County   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g Columbia University ^*  (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

Crack cocaine; Disease progression; HIV AIDS; Mortality

Indexed keywords

COCAINE; DIAMORPHINE; VIRUS RNA;

ABSTINENCE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL LOSS; DEATH; DEPRESSION; DISEASE COURSE; DRINKING; DRUG USE; EDUCATION; FEMALE; GENERAL ASPECTS OF DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INCOME; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MIXED INFECTION; MORTALITY; MULTICENTER STUDY; OBSERVATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE; SELF REPORT; SEROLOGY; SMOKING; SYMPTOM; UNITED STATES; BLOOD; CLINICAL TRIAL; COCAINE DEPENDENCE; EPIDEMIOLOGY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PROGNOSIS; SOCIOECONOMICS; VIROLOGY; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; COCAINE-RELATED DISORDERS; CRACK COCAINE; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PROGNOSIS; RNA, VIRAL; SOCIOECONOMIC FACTORS; UNITED STATES; VIRAL LOAD;

EID: 49849094871     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830507f2     Document Type: Article

References (36)

1. Xu W, Flick T, Mitchel J, Knowles C, Ault K. Cocaine effects on immunocompetent cells: an observation of in vitro cocaine exposure. IntJ Immunopharmacol 1999; 21:463-472.
2. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 1998; 83:133-138.
3. Cabral GA. Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 2006; 1:280-295.
4. Nair MP, Schwartz SA, Mahajan SD, Tsiao C, Chawda RP, Whitney R, et al. Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J Neuroimmunol 2004; 157:56-60.
5. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seropre-valence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health 1998; 88:108-113.
6. Vittinghoff E, Hessol NA, Bacchetti P, Fusaro RE, Holmberg SD, Buchbinder SP. Cofactors for HIV disease progression in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr 2001; 27:308-314.
7. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective study of HIV disease progression in female and male drug users. AIDS 1999; 13:257-262.
8. Arnsten JH, Dernas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002; 17:377-381.
9. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-259.
10. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412-420.
11. Rompalo AM, Shah N, Margolick JB, Farzadegan H, Arnsten J, Schuman P, et al. Evaluation of possible effects of continued drug use on HIV progression among women. Int J STD AIDS 2004; 15:322-327.
12. Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, et al. Effect of hard-drug use of CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr 2004; 37:1423-1430.
13. Kapadia F, Cook JA, Cohen MH. The relationship between noninjection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 2005; 100:990-1002.
14. Galai N, Vlahov D, Bareta JC, Wang C, Cohn S, Sterling TR. Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users. J Acquir Immune Defic Syndr 2005; 38:74-81.
15. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22:369-378.
16. Pezzotti P, Galai N, Vlahov D, Reza G, Lyles CM, Astemborski J. Direct comparison of time to AIDS and infectious disease between HIV seroconverter injection drug users in Italy and the Unites States: results from the ALIVE and ISS studies. J Acquir Immune Defic Syndr 1999; 20:275-282.
17. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41:1027-1034.
18. Anastos K, Kalish LA, Hessol N, Weiser B, Melnick S, Burns D, et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1 -infected women: results of the Women's Interagency HIV Study. AIDS 1999; 13:1717-1726.
19. Cook JA, Grey DD, Burke JK, Cohen MH, Gurtman AC, Richardson JL, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94:1133-1140.
20. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study: WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
21. Centers for Disease Control 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992; 41:1-19.
22. Cohen MH, French AL, Benning L, Kovacs A, Anastos KS, Young M, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113:91-98.
23. Paterson D, Swindells S, Mohr J, BresterM, Vergis EN, SquierC, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.Ann Intern Med 2000; 133:21-30.
24. Wilson T, Barron Y, Cohen MH, Richardson J, Greenblatt R, Sacks HS, etal., Women's Interagency HIV Study. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis 2002; 34:529-534.
25. Hedeker D, Gibbons RD. MIXOR: a computer program for mixed-effects ordinal regression analysis. Comput Methods Programs Biomed 1996; 49:157-176.
26. Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1979; 1:385-401.
27. Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, et al., Antiretroviral Treatment and Access Study Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS 2005; 19:423-431.
28. Crisp BR, Williams M, Timpson S, Ross MW. Medication compliance and satisfaction with treatment for HIV disease in a sample of African-American crack cocaine smokers. AIDS Behav2004; 8:199-206.
29. Burke-Miller JK, Cook JA, Cohen MH, Hessol NA, Wilson TE, Richardson JL, et al. Longitudinal relationships between use of highly active antiretroviral therapy and satisfaction with care among women living with HIV/AIDS. Am J Public Health 2006; 96:1044-1051.
30. SharpeTT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health 2004; 29:117-127.
31. Cook JA, Grey DD, Burke-Miller JK, Cohen MH, Vlahov D, Kapadia F, et al. Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend 2007; 89:74-81.
32. Stone VE. Optimizing the care of minority patients with HIV/ AIDS. Clin Infect Dis 2004; 38:400-404.
33. Johnson SD, Cunningham-Williams RM, Cottler LB. A tripartite of HIV-risk for African American women: the intersection of drug use, violence, and depression. Drug Alcohol Depend 2003; 70:169-175.
34. Reiber C, Ramirez A, Parent D, Rawson RA. Predicting treatment success at multiple timepoints in diverse patient populations of cocaine-dependent individuals. Drug Alcohol Depend 2002; 68:35-48.
35. Fisk D, Rakfeldt J, McCormack E. Assertive outreach: an effective strategy for engaging homeless persons with substance use disorders into treatment. Am J Drug Alcohol Abuse 2006; 32:479-486.
36. Gielen AC, McDonnell KA, Wu AW, O'Campo P, Faden R. Quality of life among women living with HIV: the importance of violence, social support, and self care behaviors. Soc Sci Med 2001; 52:315-322.